Contents

Abstract

SCYX-6759, the first member of a new class of anti-trypanosomal drugs, was discovered by a collaboration of DNDi, Anacor, PACE University and Scynexis. It was found that it achieved 100% efficacy in a murine stage 2 human African trypanosiomiasis (HAT) model (using Trypanosoma brucei), that it readily crossed the blood-brain and blood-testicular barriers, and that its efficacy could be predicted from brain exposure. Research on SCYX-6759 led to the development of SCYX-7158, a pre-clinical candidate for HAT treatment.

Help us improve GOV.UK

Help us improve GOV.UK

To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.